Kenvue Inc. filings document the public-company disclosures of a pure-play consumer health issuer with brands including Tylenol, Listerine, Johnson’s, Aveeno, Neutrogena and BAND-AID Brand. Its SEC record includes material-event reports, proxy and governance disclosures, shareholder voting matters, capital-structure information, operating and financial results, and consumer-health regulatory topics.
The company’s filings also cover executive officer appointments and compensatory arrangements, material definitive agreements, risk-factor disclosures and common-stock matters. Proxy materials and Form 8-K reports provide formal records of board governance, security-holder votes and other events affecting Kenvue’s corporate structure and reporting obligations.
Kenvue Inc. Form 3 discloses that Anindya Dasgupta, Group President APAC and an officer of the company, filed an initial ownership statement dated 07/14/2025. The filing states no securities are beneficially owned by the reporting person. The submission includes a Power of Attorney reference and is signed by an attorney-in-fact on 08/27/2025.
Kenvue Inc. (KVUE) Form 3 discloses an initial beneficial ownership filing for Michael Wondrasch, listed as Chief Tech & Data Officer and an officer/director. The report identifies the triggering event date as 08/25/2025 and states that no securities are beneficially owned by the reporting person. The filing was signed by an attorney-in-fact, Alla Berenshteyn, on 08/27/2025. The form references an attached Power of Attorney (Exhibit 24).
T. Rowe Price Associates, Inc. reports beneficial ownership of 168,318,661 shares of Kenvue Inc. common stock, equal to 8.8% of the class, in a Schedule 13G filing (Amendment No. 4). The filing shows sole voting power over 158,120,414 shares and sole dispositive power over 168,041,407 shares, and explicitly states the holdings are held in the ordinary course of business and not for the purpose of changing control.
The document identifies the issuer (CUSIP 49177J102), provides the issuer address for Kenvue, lists T. Rowe Price Associates, Inc. as the reporting person (Maryland), and is signed by Ellen York, Vice President, dated 08/14/2025 with the reportable event date of 06/30/2025.
Event: On August 7, 2025, Kenvue Inc. (KVUE) furnished a Current Report on Form 8-K announcing that it issued a press release (Exhibit 99.1) reporting its financial results for the fiscal second quarter ended June 29, 2025.
Disclosure status and exhibits: The filing states the information is furnished, not filed, and therefore is not subject to Section 18 liability or incorporated by reference except by specific reference. The filing attaches Exhibit 99.1 (press release dated August 7, 2025) and Exhibit 104 (cover page in Inline XBRL). The report is signed by CFO Amit Banati on August 7, 2025.
On 14 July 2025, Kenvue Inc. (NYSE: KVUE) filed a Form 8-K disclosing three material items.
Item 2.02 – Preliminary Q2 results: A press release (Exhibit 99.1) announced select, unaudited second-quarter figures; no numbers appear in the filing. Full Q2 results and updated FY-25 guidance are scheduled for 7 Aug 2025.
Item 5.02 – Leadership change: CEO Thibaut Mongon resigned from both the CEO post and the Board effective 14 Jul 2025, qualifying for standard severance and “retirement” equity treatment. The Board appointed independent director Kirk L. Perry as interim CEO. His offer letter (Exhibit 10.1) provides (i) $1.25 million annual salary, (ii) up to $1.5 million performance-based cash award payable when a permanent CEO is installed, (iii) $5 million in equity (50% stock options, 50% RSUs) vesting after one year, and (iv) up to $25,000 legal-fee reimbursement. Perry will not join the Severance Plan and will receive no additional Board fees.
Item 8.01 – Strategic review: The Board formed a five-member Strategic Review Committee, chaired by Melanie L. Healey and advised by Centerview Partners and McKinsey & Co., to evaluate alternatives such as brand-portfolio optimization aimed at accelerating profitable growth and “unlocking inherent value.” No timeline or specific options were disclosed.
The filing includes standard forward-looking disclaimers and lists three exhibits: the offer letter, the press release, and the Inline XBRL cover page.
Investor takeaway: The sudden CEO departure injects uncertainty, yet the swift appointment of an experienced interim leader and initiation of a strategic review indicate proactive Board engagement. More clarity should emerge with Q2 earnings on 7 Aug 2025.